Danazol induced cholestasis: pathogenetic hypothesis

Panminerva medica · 1997 · vol. 39(3) , pp. 244–7 · PMID:9360432 · W2273871125
Review OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-10-01 ⓘ

This paper hypothesizes that genetic alterations in alpha-1 antitrypsin and P-glycoprotein, alongside other mechanisms, explain the onset and varying severity of danazol-induced cholestasis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Numerous mechanisms have been proposed to account for deficient bilirubin excretion and the pathogenesis of estrogen and steroid (danazol) induced intrahepatic cholestasis. Our hypothesis is based on the fact that danazol is administered in the treatment of pulmonary emphysema because it stimulates synthesis of alpha-1 antitrypsin and that other estrogen glucuro-conjugated metabolites are P-glycoprotein substrates. We believe that genetic alterations of alpha-1 antitrypsin and P-glycoprotein, either alone or in association with known pathogenetic mechanisms, may explain the onset of danazol induced cholestasis and justify the difference in its varying duration and intensity.

My notes (saved in your browser only)

MeSH descriptors

Cholestasis, Intrahepatic Danazol Cholestasis, Intrahepatic Cholestasis, Intrahepatic Cholestasis, Intrahepatic Danazol Humans

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-10T10:33:38.105484+00:00
pubmed
last seen: 2026-10-08T22:00:28.864438+00:00
License: CC0 · commercial use OK